NeoGenomics, Inc. (NASDAQ:NEO) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.18. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $258.23 million.
NeoGenomics, Inc. (NASDAQ NEO) traded down 0.97% during midday trading on Friday, hitting $9.16. 258,607 shares of the stock traded hands. NeoGenomics, Inc. has a one year low of $6.90 and a one year high of $9.93. The company’s market cap is $727.19 million. The company’s 50 day moving average is $9.20 and its 200-day moving average is $8.26.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The company had revenue of $66.09 million for the quarter, compared to the consensus estimate of $62.95 million. During the same quarter in the prior year, the firm earned $0.04 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, equities research analysts forecast that NeoGenomics, Inc. will post $0.18 EPS for the current fiscal year.
In related news, insider Steven A. Ross sold 70,833 shares of the firm’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $7.76, for a total transaction of $549,664.08. Following the completion of the sale, the insider now directly owns 4,500 shares of the company’s stock, valued at approximately $34,920. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Jennifer Balliet sold 3,334 shares of the stock in a transaction on Friday, May 26th. The shares were sold at an average price of $7.50, for a total transaction of $25,005.00. Following the transaction, the vice president now owns 10,049 shares in the company, valued at $75,367.50. The disclosure for this sale can be found here. Insiders have sold 84,890 shares of company stock valued at $665,707 in the last ninety days. 12.20% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/19/neogenomics-inc-neo-updates-fy17-earnings-guidance-updated-updated-updated.html.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
What are top analysts saying about NeoGenomics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NeoGenomics Inc. and related companies.